Impact Factor 6.244 | CiteScore 3.9
More on impact ›
Submit your manuscript
Scope
The objective of the Skin Cancer section is to expand our understanding of molecular and cellular mechanisms involved in skin cancer progression. Moreover, the section is dedicated to the publication of high-quality clinical, translational research as well as bioinformatics studies in a timely manner.
Read moreScope
The objective of the Skin Cancer section is to expand our understanding of molecular and cellular mechanisms involved in skin cancer progression. Moreover, the section is dedicated to the publication of high-quality clinical, translational research as well as bioinformatics studies in a timely manner.
We are especially interested in receiving manuscripts centred on the fields of melanoma and non-melanoma skin cancer (NMSC), including basal cell carcinomas (BCCs), squamous cell carcinomas (SCCs), cutaneous T-cell lymphoma (CTLC), benign tumors as well as rarer forms of NMSC such as sebaceous gland carcinoma, Merkel cell carcinoma, angiosarcoma, and dermatofibrosarcoma protuberans (DFSP).
Submission of preclinical and clinical trials as well as case reports are also welcome.
Specific areas of interest include:
- Cancer stem cells
- Tumor microenvironment
- Mechanisms of carcinogenesis, progression and metastasis
- Resistance to therapy
- Strategies for secondary prevention
- Biomarkers of progression
- Epidemiology of skin cancer
- Advances in diagnostic, prognostic and predictive biomarkers development
- Therapeutic approaches and drug development of various modalities (targeted therapy, immunotherapies, chemotherapy, radiation therapy, surgery, combination therapies)
Additional quality and content requirements:
- Negative trial results will not preclude consideration.
- Authors should demonstrate the biological effects on a minimum of two well-authenticated cancer cell lines.
- While we welcome meta-analyses and descriptive studies, these should be based on statistical methods or systematic reviews and should bring new insights into the mechanisms of carcinogenesis.
- Case Reports should include correlative data and expand the current knowledge on the pathophysiological and clinical manifestations of cancer while discussing the cellular and molecular levels of the disease.
Indexed in: PubMed, PubMed Central (PMC), Scopus, Web of Science Science Citation Index Expanded (SCIE), Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), CLOCKSS
PMCID: NA
Skin Cancer welcomes submissions of the following article types: Case Report, Clinical Trial, Correction, Editorial, Hypothesis and Theory, Mini Review, Opinion, Original Research, Perspective, Review and Systematic Review.
All manuscripts must be submitted directly to the section Skin Cancer, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Frontiers Editorial Office
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Switzerland
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
Frontiers Support
Tel +41(0)21 510 17 10
Fax +41 (0)21 510 17 01
support@frontiersin.org
There are no results to display.
Click on any of the keywords to find further editors related to it.
- Article(s) found
- Latest
- Most viewed
This section has no articles.
There are no articles to display. Please try changing the filters.
- Research Topic(s) found
- Latest
- Most viewed
Contact Editorial Office
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Switzerland
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact oncology.editorial.office@frontiersin.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact oncology@frontiersin.org
Tel +41(0)21 510 17 10
Fax +41 (0)21 510 17 01
For technical issues, please visit our Frontiers Help Center, or contact our IT HelpDesk team at support@frontiersin.org